12/14
01:26 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at
Wall Stre
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at
Wall Stre
11/22
08:12 am
mnpr
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]
Low
Report
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]
11/14
07:22 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
11/14
05:16 am
mnpr
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]
High
Report
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]
11/13
08:38 am
mnpr
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]
Medium
Report
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]
11/13
08:00 am
mnpr
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
Medium
Report
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
11/11
07:17 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/25
12:09 pm
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/17
10:26 pm
mnpr
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy [Yahoo! Finance]
Medium
Report
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy [Yahoo! Finance]
10/15
08:00 am
mnpr
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
Medium
Report
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
10/14
07:59 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
10/13
07:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $125.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $125.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
10/11
06:14 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Jones Trading from a "hold" rating to a "strong-buy" rating.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Jones Trading from a "hold" rating to a "strong-buy" rating.
10/10
05:21 pm
mnpr
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted [Seeking Alpha]
High
Report
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted [Seeking Alpha]
10/6
08:44 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $142.00 price target on by analysts at Raymond James Financial, Inc..
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $142.00 price target on by analysts at Raymond James Financial, Inc..
10/2
10:03 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $115.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $115.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
9/29
09:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $105.00 price target on by analysts at HC Wainwright.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $105.00 price target on by analysts at HC Wainwright.